Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
53
QNCX Quote, Financials, Valuation and Earnings
Last price:
$3.53
Seasonality move
:
-7.09%
Day range:
$3.34 - $3.68
52-week range:
$0.72 - $4.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
187.22x
Volume:
388.3K
Avg. volume:
941.7K
1-year change:
103.43%
Market cap:
$198.2M
Revenue:
--
EPS (TTM):
-$1.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QNCX
Quince Therapeutics, Inc.
|
-- | -$0.20 | -- | -38.95% | $7.67 |
|
MASI
Masimo Corp.
|
$398.2M | $1.43 | -32.15% | 565.51% | $183.75 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QNCX
Quince Therapeutics, Inc.
|
$3.56 | $7.67 | $198.2M | -- | $0.00 | 0% | -- |
|
MASI
Masimo Corp.
|
$132.76 | $183.75 | $7.1B | 116.80x | $0.00 | 0% | 4.20x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QNCX
Quince Therapeutics, Inc.
|
94.44% | 1.702 | 20.26% | 1.01x |
|
MASI
Masimo Corp.
|
41.99% | 0.805 | 7.4% | 1.68x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QNCX
Quince Therapeutics, Inc.
|
-$36K | -$11.4M | -151.58% | -267.62% | -- | -$10M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Quince Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns QNCX or MASI?
Masimo Corp. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of 14.46%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About QNCX or MASI?
Quince Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 115.36%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 38.41%. Given that Quince Therapeutics, Inc. has higher upside potential than Masimo Corp., analysts believe Quince Therapeutics, Inc. is more attractive than Masimo Corp..
Company Buy Ratings Hold Ratings Sell Ratings QNCXQuince Therapeutics, Inc.4 0 0 MASIMasimo Corp.4 3 0 -
Is QNCX or MASI More Risky?
Quince Therapeutics, Inc. has a beta of 1.033, which suggesting that the stock is 3.262% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.
-
Which is a Better Dividend Stock QNCX or MASI?
Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNCX or MASI?
Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Quince Therapeutics, Inc.'s net income of -$13.4M is lower than Masimo Corp.'s net income of $53.7M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 4.20x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M MASIMasimo Corp.4.20x 116.80x $371.5M $53.7M
-
Which has Higher Returns QNCX or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of -255.85%. Quince Therapeutics, Inc.'s return on equity of -267.62% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About QNCX or NBY?
Quince Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 115.36%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Quince Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Quince Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QNCXQuince Therapeutics, Inc.4 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is QNCX or NBY More Risky?
Quince Therapeutics, Inc. has a beta of 1.033, which suggesting that the stock is 3.262% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock QNCX or NBY?
Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNCX or NBY?
Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Quince Therapeutics, Inc.'s net income of -$13.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns QNCX or OGEN?
Oragenics, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of --. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About QNCX or OGEN?
Quince Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 115.36%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Oragenics, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than Quince Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QNCXQuince Therapeutics, Inc.4 0 0 OGENOragenics, Inc.1 0 0 -
Is QNCX or OGEN More Risky?
Quince Therapeutics, Inc. has a beta of 1.033, which suggesting that the stock is 3.262% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock QNCX or OGEN?
Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNCX or OGEN?
Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Quince Therapeutics, Inc.'s net income of -$13.4M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns QNCX or PTN?
Palatin Technologies has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of --. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About QNCX or PTN?
Quince Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 115.36%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Quince Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Quince Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QNCXQuince Therapeutics, Inc.4 0 0 PTNPalatin Technologies0 0 0 -
Is QNCX or PTN More Risky?
Quince Therapeutics, Inc. has a beta of 1.033, which suggesting that the stock is 3.262% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock QNCX or PTN?
Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNCX or PTN?
Quince Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Quince Therapeutics, Inc.'s net income of -$13.4M is higher than Palatin Technologies's net income of --. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns QNCX or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Quince Therapeutics, Inc.'s net margin of --. Quince Therapeutics, Inc.'s return on equity of -267.62% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital QNCXQuince Therapeutics, Inc.-- -$0.25 $19.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About QNCX or TOVX?
Quince Therapeutics, Inc. has a consensus price target of $7.67, signalling upside risk potential of 115.36%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Quince Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Quince Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QNCXQuince Therapeutics, Inc.4 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is QNCX or TOVX More Risky?
Quince Therapeutics, Inc. has a beta of 1.033, which suggesting that the stock is 3.262% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock QNCX or TOVX?
Quince Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quince Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QNCX or TOVX?
Quince Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Quince Therapeutics, Inc.'s net income of -$13.4M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Quince Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quince Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QNCXQuince Therapeutics, Inc.-- -- -- -$13.4M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
